

# Gabriella De Vita

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5890129/publications.pdf>

Version: 2024-02-01

54  
papers

7,014  
citations

218677

26  
h-index

168389

53  
g-index

54  
all docs

54  
docs citations

54  
times ranked

10855  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>NKX2-1</i> mutation associated to familial brain-“lung” thyroid syndrome. <i>Clinical Genetics</i> , 2021, 100, 114-116.	2.0	3
2	Human Trisomic iPSCs from Down Syndrome Fibroblasts Manifest Mitochondrial Alterations Early during Neuronal Differentiation. <i>Biology</i> , 2021, 10, 609.	2.8	11
3	FOXE1-Dependent Regulation of Macrophage Chemotaxis by Thyroid Cells In Vitro and In Vivo. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7666.	4.1	2
4	FOXE1 Gene Dosage Affects Thyroid Cancer Histology and Differentiation In Vivo. <i>International Journal of Molecular Sciences</i> , 2021, 22, 25.	4.1	15
5	HMGA1-pseudogene7 transgenic mice develop B cell lymphomas. <i>Scientific Reports</i> , 2020, 10, 7057.	3.3	11
6	A ceRNA Circuitry Involving the Long Noncoding RNA Klhl14-AS, Pax8, and Bcl2 Drives Thyroid Carcinogenesis. <i>Cancer Research</i> , 2019, 79, 5746-5757.	0.9	23
7	Double knock-out of <i>Hmga1</i> and <i>Hipk2</i> genes causes perinatal death associated to respiratory distress and thyroid abnormalities in mice. <i>Cell Death and Disease</i> , 2019, 10, 747.	6.3	6
8	The Metallophosphoesterase-Domain-Containing Protein 2 (MPPED2) Gene Acts as Tumor Suppressor in Breast Cancer. <i>Cancers</i> , 2019, 11, 797.	3.7	11
9	Dual Oncogenic/Anti-Oncogenic Role of PATZ1 in FRTL5 Rat Thyroid Cells Transformed by the Ha-RasV12 Oncogene. <i>Genes</i> , 2019, 10, 127.	2.4	6
10	A Toxicogenomic Approach Reveals a Novel Gene Regulatory Network Active in In Vitro and In Vivo Models of Thyroid Carcinogenesis. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 122.	2.6	7
11	DNAJC17 is localized in nuclear speckles and interacts with splicing machinery components. <i>Scientific Reports</i> , 2018, 8, 7794.	3.3	10
12	Role of <i>Dicer1</i> in thyroid cell proliferation and differentiation. <i>Cell Cycle</i> , 2017, 16, 2282-2289.	2.6	13
13	Tissue- and Cell Type-Specific Expression of the Long Noncoding RNA Klhl14-AS in Mouse. <i>International Journal of Genomics</i> , 2017, 2017, 1-7.	1.6	18
14	PATZ1 is a target of miR-29b that is induced by Ha-Ras oncogene in rat thyroid cells. <i>Scientific Reports</i> , 2016, 6, 25268.	3.3	11
15	Mice lacking microRNAs in Pax8-expressing cells develop hypothyroidism and end-stage renal failure. <i>BMC Molecular Biology</i> , 2016, 17, 11.	3.0	14
16	Clinical relevance of thyroid cell models in redox research. <i>Cancer Cell International</i> , 2015, 15, 113.	4.1	10
17	Selective Dicer Suppression in the Kidney Alters GSK3 $\beta$ -Catenin Pathways Promoting a Glomerulocystic Disease. <i>PLoS ONE</i> , 2015, 10, e0119142.	2.5	31
18	<i>Ras</i> Oncogene-Mediated Progressive Silencing of Extracellular Superoxide Dismutase in Tumorigenesis. <i>BioMed Research International</i> , 2015, 2015, 1-13.	1.9	17

#	ARTICLE	IF	CITATIONS
19	Wnt4 inhibits cell motility induced by oncogenic Ras. <i>Oncogene</i> , 2013, 32, 4110-4119.	5.9	17
20	Upregulation of miR-21 by Ras in vivo and its role in tumor growth. <i>Oncogene</i> , 2011, 30, 275-286.	5.9	130
21	The microRNA-Processing Enzyme Dicer Is Essential for Thyroid Function. <i>PLoS ONE</i> , 2011, 6, e27648.	2.5	52
22	An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. <i>Oncogene</i> , 2009, 28, 73-84.	5.9	230
23	RET/Papillary Thyroid Carcinoma Oncogenic Signaling through the Rap1 Small GTPase. <i>Cancer Research</i> , 2007, 67, 381-390.	0.9	50
24	A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing. <i>Cell</i> , 2007, 129, 1401-1414.	28.9	3,390
25	p38 $\beta$ MAP Kinase as a Sensor of Reactive Oxygen Species in Tumorigenesis. <i>Cancer Cell</i> , 2007, 11, 191-205.	16.8	358
26	A Genetic Screen Implicates miRNA-372 and miRNA-373 as Oncogenes in Testicular Germ Cell Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2007, 604, 17-46.	1.6	83
27	A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors. <i>Cell</i> , 2006, 124, 1169-1181.	28.9	1,186
28	Replacement of K $\alpha$ Ras with H $\alpha$ Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice. <i>EMBO Reports</i> , 2005, 6, 432-437.	4.5	117
29	Dose-Dependent Inhibition of Thyroid Differentiation by RAS Oncogenes. <i>Molecular Endocrinology</i> , 2005, 19, 76-89.	3.7	55
30	Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. <i>Oncogene</i> , 2003, 22, 246-255.	5.9	46
31	The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. <i>Oncogene</i> , 2001, 20, 209-218.	5.9	57
32	Association between the expression of E1A oncogene and increased sensitivity to growth inhibition induced by sustained levels of cAMP in rat thyroid cells. <i>European Journal of Endocrinology</i> , 2000, 142, 286-293.	3.7	4
33	Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. <i>Cancer Research</i> , 2000, 60, 3727-31.	0.9	70
34	Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. <i>Cancer Research</i> , 2000, 60, 3916-20.	0.9	27
35	Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site. <i>Human Molecular Genetics</i> , 1999, 8, 1989-1999.	2.9	52
36	Different mutations of the RET gene cause different human tumoral diseases. <i>Biochimie</i> , 1999, 81, 397-402.	2.6	12

#	ARTICLE	IF	CITATIONS
37	Dual effect on the RET receptor of MEN2 mutations affecting specific extracytoplasmic cysteines. <i>Oncogene</i> , 1998, 17, 2851-2861.	5.9	97
38	Molecular biology of the MEN2 gene. <i>Journal of Internal Medicine</i> , 1998, 243, 505-508.	6.0	42
39	Glial Cell Line-Derived Neurotrophic Factor Differentially Stimulates Ret Mutants Associated with the Multiple Endocrine Neoplasia Type 2 Syndromes and Hirschsprung's Disease. <i>Endocrinology</i> , 1998, 139, 3613-3619.	2.8	32
40	Glial Cell Line-Derived Neurotrophic Factor Differentially Stimulates Ret Mutants Associated with the Multiple Endocrine Neoplasia Type 2 Syndromes and Hirschsprung's Disease. <i>Endocrinology</i> , 1998, 139, 3613-3619.	2.8	11
41	p53 genes mutated in the DNA binding site or at a specific COOH-terminal site exert divergent effects on thyroid cell growth and differentiation. <i>Cancer Research</i> , 1998, 58, 2888-94.	0.9	8
42	Only the Substitution of Methionine 918 with a Threonine and Not with Other Residues Activates RET Transforming Potential*. <i>Endocrinology</i> , 1997, 138, 1450-1455.	2.8	10
43	Glial cell line-derived neurotrophic factor (GDNF) stimulates ret activity. <i>Rendiconti Lincei</i> , 1997, 8, 139-149.	2.2	0
44	Only the Substitution of Methionine 918 with a Threonine and Not with Other Residues Activates RET Transforming Potential. <i>Endocrinology</i> , 1997, 138, 1450-1455.	2.8	7
45	The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. <i>Cancer Research</i> , 1997, 57, 391-5.	0.9	58
46	A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 7933-7937.	7.1	34
47	Molecular heterogeneity of RET loss of function in Hirschsprung's disease.. <i>EMBO Journal</i> , 1996, 15, 2717-2725.	7.8	109
48	Ligand Stimulation of a Ret Chimeric Receptor Carrying the Activating Mutation Responsible for the Multiple Endocrine Neoplasia Type 2B. <i>Journal of Biological Chemistry</i> , 1996, 271, 29497-29501.	3.4	13
49	Molecular heterogeneity of RET loss of function in Hirschsprung's disease. <i>EMBO Journal</i> , 1996, 15, 2717-25.	7.8	30
50	A mutated p53 gene alters thyroid cell differentiation. <i>Oncogene</i> , 1995, 11, 2029-37.	5.9	22
51	Activated RET/PTC oncogene elicits immediate early and delayed response genes in PC12 cells. <i>Oncogene</i> , 1995, 11, 107-12.	5.9	20
52	Expression of homeobox-containing genes in primary and metastatic colorectal cancer. <i>European Journal of Cancer</i> , 1993, 29, 887-893.	2.8	131
53	Coordinate regulation of HOX genes in human hematopoietic cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 6348-6352.	7.1	169
54	Two point mutations are responsible for G6PD polymorphism in Sardinia. <i>American Journal of Human Genetics</i> , 1989, 44, 233-40.	6.2	66